Customize
Quick Links
Specialties

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources

PER Pulse™ Recaps for Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers focuses on areas of clinical challenge encountered by practicing oncologists, along with emerging immunotherapeutic approaches being developed to tackle these challenges.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers

Release Date: April 28, 2017
Expiration Date: April 28, 2018
Media: Internet - based

 

Activity Overview

This activity focuses on standards of care and emerging strategies in immunotherapy for cancers of the lung, head and neck, and bladder. It features a series of short video interviews with leading experts in the field. The content and interviews are based on presentations given in February 2017 at Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers, a live symposium held adjunct to a major immuno-oncology conference that took place in Orlando, Florida. In their interviews, program chair Roy Herbst, MD, PhD; Ezra Cohen, MD; Robert Ferris, MD, PhD; and Daniel Petrylak, MD, offer guidance and perspective on standards of care, the clinical implication of new data, and novel investigational agents and approaches. This program is geared to meet the needs of busy researchers and clinicians who strive to advance the management of patients with these tumors.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

CME Activity Table of Contents

  • Case 1: Frontline Therapy for Squamous Non–Small Cell Lung Cancer
    Roy Herbst, MD, PhD
  • Case 2: p16-Positive, HPV-Positive Head and Neck Squamous Cell Carcinoma
    Robert Ferris, MD, PhD
  • Case 3: Metastatic Cisplatin-Refractory Urothelial Carcinoma
    Daniel Petrylak, MD
  • Case 4: Pneumonitis in a Patient Receiving Anti–PD-1 Therapy for Non–Small Cell Lung Cancer
    Ezra Cohen, MD

Requirements for Successful Completion

  • You will need to login to participate in the activity.
  • Each presentation may contain interactive questions. You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video” will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation, and then click on “request for credit”. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals are invited to participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  • Explain clinically unmet needs in the management of non–small cell lung cancer, head and neck squamous cell carcinoma (HNSCC), and bladder cancer
  • Describe how the immune system can be harnessed to treat cancer and the mechanistic rationale for the application of checkpoint inhibition strategies to target specific solid tumors
  • Interpret recent findings from clinical trials conducted with immuno-oncology strategies for the treatment of lung cancer, HNSCC, and bladder cancer
  • Describe the current status of biomarkers as a method to personalize care with the use of immuno-oncology strategies
  • Evaluate methods to mitigate treatment-related toxicities via proactive mitigation and management of immune-related adverse events (irAEs)

Faculty, Staff, and Planners' Disclosures

Faculty

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Disclosure: AstraZeneca, Eli Lilly, Genentech/Roche, Merck, Pfizer; Grant/Research Support: Genentech, Merck

Ezra Cohen, MD
Associate Director, Moores Cancer Center
Professor of Medicine
UC San Diego Health - La Jolla
La Jolla, CA
 

Disclosure: Consultant: Eisai; Pfizer; Merck; AstraZeneca; Bristol-Myers Squibb; Human Longevity;

Robert L. Ferris, MD, PhD, FACS
Professor, Vice-Chair for Clinical Operations
Chief, Division of Head and Neck Surgery Departments of Otolaryngology, Radiation
Oncology, and Immunology
Co-Leader, Cancer Immunology Program
University of Pittsburgh Cancer Institute
Pittsburg, PA

Disclosure: Grant/Research Support: AstraZeneca/MedImmune, Bristol-Myers Squibb, VentiRx Pharmaceuticals; Advisory Board: AstraZeneca/MedImmune, Bristol-Myers Squibb, Lilly, Merck, Pfizer; Clinical Trial: AstraZeneca/MedImmune, Bristol-Myers Squibb, Merck

Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology)
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
New Haven, CT
 

Disclosure: Grant/Research Support: OncoGenex, Progenics, Johnson & Johnson, Merck, Millennium, Medivation, Pfizer, Roche Laboratories, Tyme Pharmaceuticals; Consultant: Bayer, Bellicum, Dendreon, Sanofi-Aventis, Johnson & Johnson, Exelixis, Ferring, Millennium, Medivation, Pfizer, Roche Laboratories, Tyme Pharmaceuticals; Stock/Shareholder: Bellicum, Tyme.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.




PER Pulse™ Recap (1 of 3)

Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in February 2017 in Orlando, Fla. During this online activity, expert faculty discuss immunotherapy-based standards of care and emerging strategies for a variety of solid tumors. It features commentary on:

  • Frontline therapy for squamous non-small cell lung cancer (NSCLC) by Roy Herbst, MD, PhD
  • Management of p16-positive (cyclin-dependent kinase inhibitor 2A), human papilloma virus (HPV)-positive, head and neck squamous cell carcinoma (HNSCC) by Robert Ferris, MD, PhD
  • Treatment of metastatic urothelial carcinoma that has progressed on platinum therapy by Daniel Petrylak, MD
  • Adverse event (AE) management for patients receiving immunotherapy by Ezra Cohen, MD

The first of 1 PER Pulse™ Recaps summarizing the program focuses on Dr. Herbst’s answers to questions about frontline therapy for squamous NSCLC, during which he discussed:

  • His treatment approach with a 67-year-old female current smoker with a 47-pack per year smoking history, diagnosed with stage IV NSCLC (squamous histology, no brain metastasis)
  • Treatment plans for patients with NSCLC that has metastasized to the brain
  • Key factors that should be integrated into treatment decision-making for a patient with NSCLC and an autoimmune disorder (eg, rheumatoid arthritis) when considering immunotherapy
  • The involvement of PD-L1 (programmed death-ligand) and tumor inflammation in resistance to anti–programmed cell death 1 (PD-1) therapy in patients with NSCLC
  • Use of biomarkers/molecular testing for NSCLC in everyday practice and efforts of the Blueprint PD-L1 IHC (immunohistochemistry) Assay Comparison Project to answer questions about 4 available assays
  • Investigational strategies, such as immunotherapy-containing combination approaches (eg, CTLA4 [cytotoxic T lymphocyte associated protein 4] + PD-1 or PD-L1; PD-1 + anti-VEGFR antibody [antivascular endothelial growth factor])

 




PER Pulse™ Recap (2 of 3)

Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in February 2017 in Orlando, Fla. During this online activity, expert faculty discuss immunotherapy-based standards of care and emerging strategies for a variety of solid tumors. It features commentary on:
  • Frontline therapy for squamous non-small cell lung cancer (NSCLC) by Roy Herbst, MD, PhD
  • Management of p16-positive (cyclin-dependent kinase inhibitor 2A), human papilloma virus (HPV)-positive, head and neck squamous cell carcinoma (HNSCC) by Robert Ferris, MD, PhD
  • Treatment of metastatic urothelial carcinoma that has progressed on platinum therapy by Daniel Petrylak, MD
  • Adverse event (AE) management for patients receiving immunotherapy by Ezra Cohen, MD

The second of 1 PER Pulse™ Recaps summarizing the program focuses on Dr. Herbst’s answers to questions about frontline therapy for squamous NSCLC, during which he discussed:

  • His treatment approach with a 51-year-old male patient with a history of smoking, status postresection for a T2N2c p16-positive, HPV-positive SCC (squamous cell carcinoma) of the base of the tongue (with extracapsular disease), who presents with a lung metastases 4 months after completion of cisplatin/radiotherapy.
  • The rationale for using anti-PD-1 (programmed cell death) therapy in HNSCC, specifically the relatively common overexpression of PD-L1 (programmed death-ligand) observed in these tumors.
  • The significant unmet needs of patients with platinum-refractory HNSCC and the importance of the introduction of checkpoint inhibitory agents in this setting
  • Anticipated changes to related practice recommendations—for example, recently presented data suggest that response rates among patients with nasopharyngeal carcinomas who receive checkpoint inhibitor therapy are similar to those of patients with other types of HNSCC
  • Ongoing trials of immunotherapies in HNSCC, including anti-PD-1 or anti-PD-L1 agents combined with a CTLA4 (cytotoxic T lymphocyte associated protein 4) inhibitor, chemotherapy, or chemoradiation—trials are being conducted in the setting of recurrence ≥ 6 months after platinum therapy, recurrence < 6 months after platinum, and as curative therapy for patients with high-risk, local-regionally advanced HNSCC

 




PER Pulse™ Recap (3 of 3)

Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers is a series of short content summaries and video interviews with the faculty of a live CME-certified symposium held in February 2017 in Orlando, Fla. During this online activity, expert faculty discuss immunotherapy-based standards of care and emerging strategies for a variety of solid tumors. It features commentary on:
  • Frontline therapy for squamous non-small cell lung cancer (NSCLC) by Roy Herbst, MD, PhD
  • Management of p16-positive (cyclin-dependent kinase inhibitor 2A), human papilloma virus (HPV)-positive, head and neck squamous cell carcinoma (HNSCC) by Robert Ferris, MD, PhD
  • Treatment of metastatic urothelial carcinoma that has progressed on platinum therapy by Daniel Petrylak, MD
  • Adverse event (AE) management for patients receiving immunotherapy by Ezra Cohen, MD

The third of 1 PER Pulse™ Recaps summarizing the program focuses on Dr. Herbst’s answers to questions about frontline therapy for squamous NSCLC, during which he discussed:

  • His treatment approach with a patient who develops pneumonitis 9 weeks after initiation of pembrolizumab for metastatic non-small cell lung cancer
  • Aspects of immune-related AE (irAE) management he has found most challenging in his own practice
  • His preferences regarding oral versus intravenous steroids to treat irAEs, and his decision-making process when d switching from one to another
  • His perspectives on using infliximab to manage irAEs that are refractory to corticosteroids
  • Key considerations when distinguishing an infection from an irAE
  • How he counsels patients about the potential for irAEs

 








Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
1234567
891011121314
15161718192021
22232425262728
293031
Filter By